17th Mar 2025

Scottish Government announcement of investment to support national pharmacogenetic testing of CYP2C19 in Stroke patients and MT-RNR1 in newborn babies in NHS Scotland.

genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to note...

6th Jan 2025

Genedrive® CYP2C19 ID Kit clinical performance published

Superior performance to laboratory test and alternative available point of care platforms ge...

21st Nov 2024

NIHR and OLS Funding Package

genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces a succes...